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In this issue of The Journal of Infectious
Diseases, Dai et al reexamine the
VOICE trial (MTN 003), whose primary
study outcomes failed to indicate that
topical tenofovir, oral tenofovir, or oral
tenofovir/emtricitabine protect women
against human immunodeﬁciency virus
type 1 (HIV) infection [1]. The VOICE
trial had collected extensive plasma teno-
fovir levels, enabling the investigators to
examine protocol drug adherence with
an objective measure [2]. Hence, the in-
tent-to-treat analyses were adjusted by
Dai et al, using 2 deﬁnitions based on de-
tecting tenofovir in plasma either (1) at
least once during follow-up or (2) at 3
months of follow-up [1]. For the gel
arm only, analyses that adjusted for base-
line predictors of HIV infection risk re-
sulted in a reversal of the negative trial
results, with an adjusted relative risk for
HIV infection prevention of 0.53 (95%
conﬁdence interval, .29–.97) among
women with tenofovir ever detected and
0.40 (95% conﬁdence interval, .16–.98)
among women with tenofovir detected
at 3 months, compared with women in
the placebo arm. (We presume that the
adjusted relative risk would be similar if
nonadherent women were the compari-
son group, but this is not presented.)
Given the ability of these adjusted models
to present as-treated or per-protocol
analysis with substantially reduced con-
founding, the conclusion of no effect
was reversed, with a strong suggestion
that the topical preexposure prophylaxis
(PrEP) worked to protect gel users,
when the gel was actually used. The bio-
logical marker was not successful in pre-
dicting nonadherence in the 2 oral drug
arms.
The debate between the merits of intent-
to-treat and as-treated or per-protocol
analyses are familiar to clinical trials
methodologists [3]. Abandoning the
randomized design inherent in intent-
to-treat analyses introduces potentially
unmeasured confounding; in the case of
oral or topical PrEP, the baseline HIV in-
fection risk could differ between women
using PrEP and women not using it. If
risky behaviors or higher-risk sexual con-
tacts were more frequent among the
women who were not using the product,
then the product could look efﬁcacious,
but this would really merely be a marker
of lower risk exposure in the treated
group. Hence, randomized clinical trials
aiming to show superiority should not
rely on as-treated or per-protocol analy-
ses except as secondary data analyses to
inform future work. In contrast, for non-
inferiority trials, per-protocol or as-treated
analyses can be informative, even given
their potential biases.
The use of a biological indicator by Dai
et al as a ﬁrm measure of protocol adher-
ence is valuable for a host of studies in
which the product is being used by
study participants and the administration
of the product is therefore not in the con-
trol of the investigators. The VOICE
study was notable for many ﬁeld research
insights. First, many of the women in the
trial were disingenuous, stating that they
were using the product when they were
not. Social response bias was therefore
likely, with some individuals telling the
healthcare workers what they thought
that the workers wanted to hear about ad-
herence. This may have been a major fac-
tor in the motivations of VOICE trial
participants. Many women feared PrEP
side effects but did not want to risk alien-
ating VOICE study staff. In addition, a
desire to receive study-related remunera-
tions may have led some women to sign
up for the trial without having any ﬁrm
intention of actually using the product.
Analogous concerns may have been
factors in the negative results of the
FEM-PrEP and the FACTS trials of topi-
cal PrEP, both of which suggested no
beneﬁt of tenofovir-based microbicide
use in HIV infection prevention but had
very poor adherence among participants;
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in the face of participating women choos-
ing not to adhere to product use in high
proportions, the ability of the study to ad-
dress the original research question of bi-
ological efﬁcacy was compromised [4, 5].
In contrast, women in stable couples
relationships in the Partners PrEP and
TDF1/TDF2 studies and at-risk women
in rural South Africa in the CAPRISA
004 study had adherence rates with PrEP
(oral or topical, depending upon the trial)
that were high enough to demonstrate de-
ﬁnitive efﬁcacy [6–8]. Among men who
have sex with men, several trials and obser-
vational studies demonstrated overall trial
product efﬁcacy and effectiveness [9–12].
In the context of this entire body of work
[13], the ﬁndings of Dai et al are more eas-
ily interpreted: although women who ad-
hered to PrEP may have been different
from women who did not, the weight of
the evidence from the VOICE trial is that
the products worked to prevent HIV infec-
tion among women who used PrEP.
Whether or not subjects should be
presented with their own adherence data
during the trial, to motivate adherence, is
debatable [1, 14, 15]. On one hand, adher-
ence can be improved. On the other hand,
transient so-called white-coat adherence
may be nurtured when a subject knows
that a biological sample will be obtained
at the time of a visit. In the PrEP ﬁeld,
adherence is so critical to the biological
beneﬁts that one might advocate for mon-
itoring and feedback for new, untested
products but focus on more-practical
operational research on products and
interventions, including behavioral inter-
ventions to encourage adherence, whose
beneﬁts have been conﬁrmed in the con-
text of high adherence [16]. The value of
biological surrogates for measuring treat-
ment adherence at the trial’s end, however,
is indisputable. A negative trial result at-
tributable to nonadherence has far differ-
ent clinical and public health implications
than a negative trial result due to failure of
the product to produce the intended ther-
apeutic or preventive effect!
The biostatistical approaches taken by
Dai et al were built upon a reasonable
assumption, known as the “exclusion re-
striction” assumption in the causal litera-
ture. Speciﬁcally, if, among those with no
pharmacological evidence of adherence,
it is possible to adjust for many con-
founders such that their risk is indistin-
guishable from those on placebo, then,
under speciﬁc assumptions, adjustment
for these confounders should also enable
the efﬁcacy of the product in those who
took it to be estimated. Dai et al showed
that they could sufﬁciently adjust for such
confounding for a tenofovir gel product
but not for oral tenofovir/emtricitabine
or oral tenofovir alone. Data from other
studies can be used to infer that the null
effect for the oral formulations after this
adjustment is plausibly due to the phar-
macological measure itself, that is, that
the biological surrogate means something
different in the oral prophylaxis groups,
compared with the topical gel group. In
future trials, it might not be possible to
distinguish genuine lack of efﬁcacy, even
among adherers, from issues involving
the use of the biological surrogate. At
least to some degree, the success of the
method thus relies on already knowing
what answer to expect.
The future of topical PrEP is likely to
be as microbicides whose adherence chal-
lenges are far less than those of current
products, which require a high degree of
protocol adherence. The current trials of
nonnucleoside reverse-transcriptase in-
hibitor (NNRTI) prophylaxis use a long-
acting dapivirine-containing vaginal
ring that must be replaced once monthly,
which, it is hoped, will be a less complex
approach than daily or coitally dependent
self-dosing. Two phase 3 trials are in pro-
gress, with efﬁcacy results expected in
2016: MTN-020 (ASPIRE) and IPM 027
(The Ring Study) [17, 18].High efﬁcacy is
hoped for, since drug resistance might be
expected in breakthrough infections after
NNRTI monotherapy prophylaxis. If
highly efﬁcacious, a monthly ring could
be a vital preventive tool for women,
more popular and deployable on a public
health scale than PrEP methods for those
who require more-intensive engagement,
especially in sub-Saharan African regions
with the highest incidence of HIV infec-
tion [19]. (For anal sexual exposures
among men or women, a depot topical
ring approach is not likely to be feasible.)
Statistical methods like those presented
here by Dai et al may well be needed to
gain the most value from ongoing studies
and are most welcome in this complex
HIV prevention research arena.
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